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Compelling evidence exists that non-haematopoietic stem cells, including mesenchymal (MSCs) and
neural/progenitor stem cells (NPCs), exert a substantial beneﬁcial and therapeutic effect after trans-
plantation in experimental central nervous system (CNS) disease models through the secretion of im-
mune modulatory or neurotrophic paracrine factors.
This paracrine hypothesis has inspired an alternative outlook on the use of stem cells in regenerative
neurology. In this paradigm, signiﬁcant repair of the injured brain may be achieved by injecting the
biologics secreted by stem cells (secretome), rather than implanting stem cells themselves for direct cell
replacement. The stem cell secretome (SCS) includes cytokines, chemokines and growth factors, and has
gained increasing attention in recent years because of its multiple implications for the repair, restoration
or regeneration of injured tissues.
Thanks to recent improvements in SCS proﬁling and manipulation, investigators are now inspired to
harness the SCS as a novel alternative therapeutic option that might ensure more efﬁcient outcomes than
current stem cell-based therapies for CNS repair.
This review discusses the most recent identiﬁcation of MSC- and NPC-secreted factors, including those
that are trafﬁcked within extracellular membrane vesicles (EVs), and reﬂects on their potential effects on
brain repair. It also examines some of the most convincing advances in molecular proﬁling that have
enabled mapping of the SCS.
 2013 The Authors. Published by Elsevier Masson SAS. Open access under CC BY license.1. Introduction
Recent advances in stem cell biology hold great promise in the
development of non-haematopoietic stem cell-based therapeuticsResearch Council Stem Cell
Y, UK. Tel.: þ44 1223 331163;
of Experimental Neurology,
nstitute, 20132 Milan, Italy.
Drago), spp24@cam.ac.uk
r Masson SAS. Open access under CC for the treatment of diseases of the central nervous system (CNS),
including animal models of multiple sclerosis (MS) [1e3], Alz-
heimer’s disease (AD) [4], spinal cord injury (SCI) [5] and stroke [6].
Growing evidence suggests that the effects orchestrated by stem
cell transplants might not only be associated with the generation of
new graft-derived neurons and glial cells [7,8] and that the context
in which these cells are injected critically determines some of the
outcomes. Thus, cell replacement is not the sole way for trans-
planted stem cells to foster tissue repair in vivo [9]. It is in fact
becoming increasingly accepted that stem cells secrete a vast array
of proteins e including growth factors, cytokines, chemokines,
metabolites and bioactive lipids e that regulate their biology in an
autocrine or paracrine manner, while orchestrating multiple in-
teractions with the surrounding microenvironment (therapeutic
plasticity) [9e11]. This new concept of stem cell therapeutic plasticity
describes the various therapeutic actions of transplanted stem cellsBY license.
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microenvironments [12,13].
Among a number of promising stem cell sources, mesenchymal
stromal/stem cells (MSCs; also known as multipotent stromal cells)
and neural stem/precursor cells (NPCs) are being extensively
investigated for their capacity to signal to the host upon trans-
plantation in experimental CNS diseases. Following transplants of
both MSCs and NPCs, sustained graft-to-host exchanges of signals
has lead to trophic effects on endogenous brain cells and beneﬁcial
modulatory actions on innate and adaptive immune responses that
have ultimately promoted the healing of the injured CNS [2,14,15]. A
number of key regulatory pathways have been identiﬁed as being
shared between MSCs and NPCs, thus suggesting the existence of a
stem cell-like signalling signature that is likely to be common to
other stem/precursor cell types as well [16].
Both targeted/untargeted proteomics and metabolomics are
now being extensively applied to identify novel factors of potential
therapeutic relevance in the stem cell secretome (SCS). Moreover, the
use of gene expression approaches or culture preconditioning of
modiﬁed stem cells capable of actively releasing discrete levels of a
pro-regenerative secreted factor merits consideration and will be
an area of intensive investigation in the near future. Finally, the
development of local vs systemic stem cell-free therapeutics that
use extracellular membrane vesicles (EVs), instead of whole
parental stem cells, is emerging as an exciting new concept in
regenerative medicine [17].
Here, we have reviewed the current knowledge of the SCS from
MSCs and NPCs, and examined its potential in brain repair. We have
also discussed the on-going main investigative directions aimed at
both improving cellular (secretory) activities and characterizing the
SCS and its regulation in greater detail.
2. The stem cell secretome and its role in brain repair
2.1. Mesenchymal stem cells
MSCs are self-renewing, clonal precursors of non-haema
topoietic tissues that were ﬁrst identiﬁed in the bone marrow
(BM-MSCs) [18]. Nevertheless, intensive research efforts have
suggested alternative tissue sources that include the adipose tissue
(ASCs [19];), the dental pulp [20], the placenta [21], the umbilical
cord blood (HUCPVCs [22];), the Wharton Jelly (WJSCs [23];), ol-
factory mucosa [24], deciduous teeth [25], lung and spleen [26],
and even the brain [27]. MSCs can be expanded in vitro for some
time while retaining the potential to differentiate into mesen-
chymal cell types closely related to the germ layer of origin, such as
adipocytes, chondrocytes and osteoblasts [28]. The transplantation
of MSCs has emerged as promise for the repair or restoration of
several tissues, including the CNS [29]. That MSC transplants
possess potential for the treatment of CNS diseases has become
clear following the observation of clinical and histological recovery
shown in laboratory animals with CNS disease models after the
systemic injection of MSCs [30]. However, the mechanisms driving
the therapeutic impact of MSC transplants remain unclear. Among a
few candidate hypotheses, two main perspectives receiving atten-
tion relate to the tissue trophic and immune modulatory effects
that transplanted MSCs exert on the host [31,32].
The intracerebroventricular injection of either BM- or ASC-MSCs
has been shown to increase lifespan and body weight, ameliorate
motor function impairments, and slow the overall deterioration of
twitcher mice, as model of Krabbe’s disease (KD), by inhibition of
the type of inﬂammation associated with KD progression [33]. As
such, MSC-transplanted twitcher mice showed a signiﬁcant
reduction in cerebral inﬂammation, including a signiﬁcant decrease
in the numbers of CNS-inﬁltrating macrophages, and activatedmicroglial cells as compared to sham-treated controls [33]. Other
studies also conﬁrmed the immune modulatory properties of MSCs
after systemic cell injection in rodents affected by experimental
autoimmune encephalomyelitis (EAE), as a model of MS. The sys-
temic injection of both BM-MSCs and ASC-MSCs via immune reg-
ulatory and neurotrophic mechanisms [34e36] lead to inhibition of
autoreactive T cell responses as well as the stimulation of endog-
enous oligodendrogenesis [35e38]. Key factors responsible for
some of the observed therapeutic effects have been identiﬁed as
stem cell-secreted hepatocyte growth factor (HGF) [39,40], as well
as ﬁbroblast growth factor (FGF)-II, brain-derived neurotrophic
factor (BDNF), and platelet-derived growth factor (PDGF)-AB [34].
The effects of both HGF and MSC-CM are mediated through the
tyrosine kinase receptor cMet in vivo, and have led to enhanced
myelin repair and immune modulation, while being fully inhibited
by anti-cMet and anti-HGF antibodies [39,40]. Similar anti-
inﬂammatory effects were observed after MSC transplantation in
mice with experimental SCI, showing reduction of astro- and
micro-gliosis and enhancement of sensorimotor functions [41].
On the other hand, the transplantation of BM-MSCs delivered
into the lesion epicentre of rats with experimental SCI reduced the
lesion volume and induced axonal regrowth. In this study, the
neurite outgrowth was promoted by BM-MSC-secreted BDNF and
glial cell line-derived neurotrophic factor (GDNF) [42]. WJ-MSC or
ASC-MSCs are also rich in paracrine neuroprotective factors that
may account for protective effects in vivo after transplantation. The
intralesional transplantation of human WJ-MSCs in rats with
experimental complete spinal cord transection led to decreased
numbers of microglia and reduced astroglial scarring, and was
found associated with increased levels of neutrophil-activating
protein-2 (NAP-2), neurotrophin-3 (NT-3), FGF-II, glucocorticoid-
induced tumour necrosis factor receptor (GITR), and vascular
endothelial growth factor receptor (VEGFR)-3 [43].
In a mouse model of Huntington’s disease (HD), intrastriatally
transplanted BM-MSCs integrated in the host brain and exerted
neurotrophic effects that correlate with increased levels of laminin,
von Willebrand factor (VWF), stromal cell-derived factor-1 (SDF-1)
a, and the SDF-1 receptor CXCR4, which in turn enhanced angio-
genesis in the damaged striatum [44]. The intravenous (i.v.) injec-
tion of BM-MSCs in 6-hydroxydopamine (6-OHDA)-induced
experimental Parkinson’s disease (PD) exerted anti-apoptotic ef-
fects on host dopaminergic (DA) neurons in part via secreted SDF-1
a [45]. Rats receiving MSC transplantation showed signiﬁcant
behavioural recovery both in cylinder test and amphetamine-
induced rotation test, compared with controls [45]. Further
in vitro studies conﬁrmed the relevance of MSC-secreted SDF-1 a in
mediating some of the tissue trophic/protective effects of grafted
MSCs. As such, MSC-conditioned media (MSC-CM) displayed anti-
apoptotic effects on 6-OHDA-exposed PC12 cells in vitro and
increased dopamine (DA) release from the cells. Incubation with
anti-SDF-1a antibodies reduced the anti-apoptotic effects of the
MSC-CM and conﬁrmed a key role for MSC-secreted SDF-1 a in the
observed neuroprotection. Similarly, intrastriatally transplanted
ASC-MSCs protect against 6-OHDA-induced experimental PD in
mice [46]. Histological, electrophysiological, neurochemical and
gene expression studies suggested that the likely mechanisms by
which ASC-MSCs cell grafts rescued the nigrostriatal function
involved little direct differentiation of the stem cell graft into
functional dopaminergic neurons, rather indirectmodulation of the
oxidative stress-induced neuroinﬂammatory environment via the
secretion of GDNF, BDNF and nerve growth factor (NGF) at the level
of the lesioned substantia nigra [46].
Intravenously injected human MSCs have been found to induce
functional amelioration, reduce the infarct volume, and promote
neuroprotection in rats with experimental middle cerebral artery
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insulin-like growth factor (IGF)-1 as well as induced expression of
VEGF, epidermal growth factor (EGF) and FGF-II in the host cells
were observed in the brain of transplanted rats, as compared with
controls [47]. Interestingly, IGF-1 only was detected in vivo, sug-
gesting its direct and speciﬁc induction, e.g. by the ischaemic or
inﬂammatory environment, in transplanted MSCs. The intracere-
bral implantation of WJ-MSCs in experimental brain stroke
increased brain plasticity and modulated b1-integrin expression,
while also providing exogenous SDF-1a, BDNF and GDNF, which
were found in brain areas adjacent to the infarcted tissue [48]. The
transplantation of human ASC-MSCs also enhanced angiogenic and
neurogenic processes promoted by secreted VEGF, hepatocyte
growth factor (HGF), and transforming growth factor (TGF)-b
[49,50]. The intracerebroventricular (i.c.v.) injection of ASC-CM
reduced the infarct volume and the brain swelling of mice with
ischaemiaereperfusion experimental brain injury, by a mechanism
of neuroprotection that was dependent on secreted tissue inhibitor
of metalloproteinase-1 (TIMP-1) and progranulin [51]. The direct
acute (either 1 h or 24 h post-injury) intravenous infusion of ASC-
CM induced behavioural and learning recovery of rats with exper-
imental hypoxiaeischaemia (HI) brain injury, while markedly
reducing long-term functional cognitive and motor skill impair-
ments by a mechanism regulated by secreted IGF-1 and BDNF [52].
In vitro co-cultures with MSCs and SH-SY5Y neuroblastoma cells
showed that BM-MSCs promote neuronal/glial survival and neu-
ritogenesis through the secretion of BDNF and b-NGF [53].
Neutralizing anti-BDNF antibodies only partly inhibited these ef-
fects, thus suggesting that other factors secreted by MSC also have
neuritogenic effects [53].
The characterization of BM-MSC-conditioned media by
antibody-based protein array analyses and enzyme-linked immu-
nosorbent assays (ELISAs) showed enrichment of IGF-1, HGF, VEGF
and TGF-b, and provided evidence of their role in the increased
neuronal survival and outgrowth in vitro [54]. Individual trophic
factors, or combinations thereof, were however less effective at
promoting these effects than whole CM, thus suggesting that the
key factors responsible for regulating the MSC secretome remain to
be identiﬁed [54].
Salgado and colleagues suggested that the SCS of human um-
bilical cord perivascular cells (HUCPVCs) might contain neuro-
regulatory factors that increase cell viability and proliferation on
primary glial cultures and potentiate the proliferation of neural
progenitors as well as neuronal survival/differentiation in vitro [55].
In addition to these neuroprotective properties, ASC-MSC-
conditioned media also mediated the repair of damaged tissues
by inducing neuronal differentiation via NGF-induced activation of
50 AMP-activated protein kinase (AMPK) in neurogenic PC12 cell
line in vitro [56]. BM-MSC-secreted factors present in the condi-
tionedmediumwere also capable of promoting the proliferation, as
well as increasing the expression of glial ﬁbrillary acidic protein
(GFAP) by neural stem/precursor cells (NPCs) in vitro, which sug-
gests an effect towards differentiation into astrocytes [57]. Other
evidence implied that MSC-secreted factors might induce oligo-
dendrogenesis upon reducing the generation of astrocytes, and
promote oligodendroglial differentiation/maturation of adult NPCs,
as shown by treatment of NPCs with rat MSC-CM [58].
Some evidence supports the view that paracrine signalling
mediated by MSC-released factors in the SCS may also play an
essential immune modulatory role in brain regeneration. The im-
mune modulatory capacities of MSCs are suggested by the inhibi-
tion of T and B cell proliferation [59,60], inhibition of the
production of H2O2 from neutrophils [61], and T and NK cytotox-
icity [62], as well as the differentiation and maturation of mono-
cytes into dendritic cells [63]. Of note, these immune modulatoryproperties are not only constitutive, but also promoted by pro-
inﬂammatory cytokines such as interferon (IFN)-g, tumour necro-
sis factor (TNF)-a, and interleukins (IL)-1a and -1b that recapitulate
in vitro the main inﬂammatory signalling that MSCs are expected to
face in vivo after transplantation [64].
Several studies reported that the i.v. or intraperitoneal (i.p.)
injection of MSCs modulates immune responses in vivo to induce
peripheral tolerance and ameliorate disease in mice with EAE [65e
69]. Zappia et al. showed that i.v.-injected MSCs modulate T-cell
responses within the peripheral compartment of EAE mice in vivo,
and inhibit the proliferation of ex vivo derived T cells from MSC
EAE-treated mice, upon stimulation with the encephalitogenic
myelin oligodendrocyte glycoprotein (MOG) in vitro. In addition,
in vitro comparative analyses on tissue speciﬁc MSCs such as hu-
man BM-MSCs and ASC-MSCs revealed differences that can be
relevant to their ability to modulate immune responses after stem
cell grafts [63]. Payne et al. provided provocative evidence that
distinct immune modulatory and migratory mechanisms might
underpin the diverse therapeutic potential of human MSCs from
different tissue sources, such as BM-MSCs, ASC-MSCs and WJ-
MSCs, in vitro and in vivo after systemic MSC injection [70]. After
having characterized in vitro the above MSCs for their immune
modulatory effects, these authors assessed their therapeutic efﬁ-
cacy in vivo in mice with chronic EAE [70]. In vitro, BM-MSCs e but
not ASC-MSCs andWJ-MSCse inhibited T cell proliferation through
soluble factors present in CM that were enriched into the inﬂam-
matory cytokines TNF-a, IL-6 and IL-10. This secretion proﬁle was
not observed with ASC-MSC or WJ-MSC CM, thus suggesting that
those soluble factors secreted by BM-MSCs may account for part of
their potent in vitro immune modulatory effects. Despite this
in vitro ﬁnding, only i.v.-injected ASC-MSCs ameliorated chronic
EAE in mice. The disparity between these in vitro and in vivo ﬁnd-
ings could then reﬂect differences in the homing potential of the
three tested MSCs types, as implied by differential expression of
integrin-a4 and the inability of integrin-a4-negative BM-MSCs to
trafﬁc to the CNS [70].
Recently, induced pluripotent stem (iPS) cells have provided an
alternative source of functional MSCs for tissue repair [71]. iPSC-
derived MSCs were comparable to BM-MSCs in surface marker
expression, differentiation potential, and also in vivo regenerative
potential in the hind limb ischaemia mouse model [72].
Speciﬁc roles of secreted factors such as tryptophan catabolites
promoted by the activity of indoleamine 2,3-dioxygenase (IDO)
[40], IL-6, prostaglandin E2 (PGE2), TGF-b, HGF, leukaemia inhibi-
tory factor (LIF), and human leucocyte antigenmolecule 5 (HLA-G5)
have been associated with some of the immunosuppressive effects
of MSCs [73].
Mouse MSCs co-cultured with splenocytes in vitro inhibited T
cell proliferation via an IL-6-dependent mechanism [74]. Mouse
BM-MSCs also secreted signiﬁcant amounts of PGE2 in vitro, which
correlated with the efﬁcacy of EAE inhibition after systemic MSC
injection [75]. The immune regulation of transplanted BM-MSCs in
EAE required PGE2 and the loss of immune regulatory functions by
differentiated MSCs correlated with decreased secretion of PGE2.
These ﬁndings suggest that PGE2 secretion represents an important
mechanism in the control of autoimmune conditions in EAE [75].
Human BM-MSCs express IDO, which catalyses the conversion
of tryptophan to kynurenine and exhibits functional IDO activity,
resulting in tryptophan depletion and kynurenine production upon
stimulation with IFN-g [76,77]. Co-cultures of MSCs and mixed
lymphocyte reactions (MLRs) have been assessed for IDO activity by
measuring tryptophan-to-kynurenine conversion in MSC-CM and
in MLRs with MSCs. IDO-mediated tryptophan depletion in MSC-
CM functions as a T cell-inhibitory effector mechanism in MSC/
MLR co-cultures [76]. In addition to tryptophan depletion,
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proliferation and inducing the apoptosis of activated allogeneic T
cells [78]. Plumas et al. showed that human BM-MSCs induced
apoptosis of activated T cells and provided correlative evidence that
this took place along with conversion of tryptophan into kynur-
enine by IDO [77]. In support of this IDO hypothesis, another work
showed that the oral (or intraperitoneal) administration of syn-
thetic tryptophan metabolites suppressed the proliferation of
myelin-speciﬁc T cells and reversed paralysis in EAE mice [79].
Moreover, secretion of IL-6 by human BM-MSC triggered a
partial inhibition of dendritic cell (DC) differentiation, as shown by
a slight but signiﬁcant decrease in the percentage of mature DCs,
when cultured in the presence of IL-6-secreting MSCs [74]. Spag-
giari et al. showed that part of the inhibitory effect of human BM-
MSCs on DC maturation was mediated by PGE2 [80]. PGE2
directly added to cultures of monocytes blocked their differentia-
tion towards DCs to the same extent as BM-MSCs, and PGE2 in-
hibitors added to BM-MSC/monocyte co-cultures fully reverted the
inhibitory effects of BM-MSCs [80].
Other studies implicate TGF-b and HGF as mediators of the anti-
proliferative effect of human BM-MSCs on T cells [81]. This ﬁnding
has also been corroborated by up-regulation of TGFb, IL-10, IDO, LIF,
and HLA-G transcripts during human MSC/T cell co-cultures [82].
HLA-G alters various immune cell functions, such as NK cell and
cytotoxic T lymphocyte-mediated cytolysis [83], allogeneic T-cell
proliferation, and dendritic cell maturation [84,85]. Blocking ex-
periments with neutralizing anti-HLA-G antibodies suggested that
human BM-MSCs might use secreted HLA-G to suppress T cell
proliferation and to inhibit the expansion of CD4þ/CD25þ/Foxp3þ
regulatory T cells, as well as the NK-cell mediated cytolysis and
secretion of IFN-g [86].
More recently, BM-MSC-secreted galectin-1 and semaphorin-3A
have been identiﬁed as key additional inhibitors of T cell prolifer-
ation, while the anti-proliferative effects of MSCs on T cells are
completely reverted by blocking antibodies against galectin-1 and
semaphorin-3A, or soluble recombinant NP-1, the main receptor of
both galectin-1 and semaphorin-3A [87].
Despite all these promising observations, the precise mecha-
nisms and the factors governing the tissue trophic and immune
regulatory functions of MSCs are still far from being fully
elucidated.
2.2. Neural stem/precursor cells
Multipotent neural stem/precursor cells (NPCs), supporting self-
renewal and differentiation into neurons, astrocytes, and oligo-
dendrocytes, reside within specialized niches such as the sub-
ventricular zone (SVZ) of the lateral ventricles and the subgranular
zone (SGZ) in the dentate gyrus of the hippocampus in the adult
mammalian CNS [88]. NPCs hold great potential for the treatment
of neurological disorders, not only because they may provide a
(tissue-speciﬁc) cellular reservoir for the replacement of lost or
damaged cells, but also because of several bystander capacities,
such as tissue trophic support and immune regulation, that have
been described in vitro and in vivo following NPC transplants [89].
Neurotrophic growth factors like NGF, BDNF, ciliary neuro-
trophic factor (CNTF) and GDNF have been found to be increased
after NPC transplantation and are likely responsible for the pre-
vention of neuronal programmed cell death and glial scar forma-
tion in both primary and secondary neurodegenerative disorders e
such as SCI, ischaemic stroke, HD, PD, and demyelinating disorders
[6,90e95]. NPCs constitutively produce and secrete such neuro-
trophic factors which promote the growth of host spinal axons after
brain injuries. In addition, augmentation of natural growth factor
production by transduction with NT-3, also secreted by NPCs,extends the spectrum of host axon sensitivity to NPC grafts [92].
Interestingly, over-expression of NT-3 also resulted in a collateral
decrease in the expression of other neurotrophins, thus suggesting
the existence of a complex reciprocal interplay between different
growth factor signal transduction pathways in NPCs [92]. In
ischaemic stroke in vivo, transplanted NPCs secreted tissue trophic
factors such as VEGF, but also induced in the host the re-expression
of guidance molecules (e.g. slit/Robo signalling and thrombo-
spondins 1 and 2), through which NPCs regulate dendritic sprout-
ing, axonal plasticity and axonal transport in vitro [96]. Likewise,
striatal neuronal protection and enhanced motor function in HD
rats showing poor integration of grafted NPCs, but high levels of
NPC-secreted BDNF, both in vitro and in vivo, suggested that the
neuroprotective effects of transplanted NPCs work partly through
BDNF secretion [94]. The intrastriatal NPC transplantation in 6-
OHDA-induced experimental PD rats induced behavioural recov-
ery and protected from dopaminergic depletion by stem cells factor
(SCF)-mediated anti-apoptotic effects [97]. Mouse NPCs unilaterally
grafted into the midbrain of aged mice, which contains a large
population of dysfunctional but living dopaminergic neurons, dis-
played a strong tropism for tissue lesions and migrated towards
these critical sites to release GDNF, which prevent cell death and
facilitate the regeneration of targeted cell populations [98]. The
transplantation of Lewis X (LeX) and CXCR4 (Leþ/CXþ) NPCs into
superoxide dismutase (SOD)1-G93A transgenic mice, as a model of
amyotrophic lateral sclerosis (ALS), led to neuroprotection that
correlated with increased spinal cord levels of VEGF and IGF-1 [99].
Systemically injected (either intravenously or intrathecally) NPCs
ﬁrst promoted endogenous remyelination inmice with chronic EAE
[100]. More recently, EAE studies with i.c.-injected NPCs have
revealed that NPC-secreted PDGF-AA and FGF-II are responsible for
the activation of the proliferation of host oligodendrocyte progen-
itor cells (OPCs) and the promotion of their maturation into
remyelinating oligodendrocytes [101].
Madhavan et al. have examined the dynamics of the cross-talk
between NPCs and their cellular environment using co-cultures
with primary neural cells that are exposed to 3-nitropropionic
acid (3-NP), an inhibitor of the mitochondrial respiratory complex
II, as an in vitro model of HD-like oxidative stress. Enhanced NPC
secretion of BDNF, CNTF, and VEGF was assessed on cell culture
supernatants and was shown to stimulate a robust SOD 2-mediated
anti-apoptotic and antioxidant effect on neurons [102]. The neu-
roprotective effects of NPC-CM were also conﬁrmed by experi-
ments carried out in another in vitro model of HD with cerebral
hybrid neurons (A1) transfected with either wild type or mutant
Huntingtin [103]. When mutant Huntingtin-transfected A1 cells
were exposed to NPC-CM, a signiﬁcant reduction of Huntingtin
aggregates and levels of N-terminal proteolytic cleavages of mutant
Huntingtin were observed [103]. NPC-CM also reduced the extent
of N-methyl-D-aspartate (NMDA)-induced excitotoxic cell death in
hippocampal slice cultures. Mass spectrometry (MS) analyses on
NPC-CM identiﬁed the novel neuroprotective peptide pentitin, a
putative breakdown product of the insulin B chain [104]. Pentitin
prevented NMDA-mediated toxicity of both mature and immature
neurons, thus conﬁrming a role of this secreted factor in part of the
neuroprotection observed with NPC-CM [104]. Human NPCs
transplanted in the rat cortex 1 week post-stroke successfully
engrafted and migrated towards the lesion. Interestingly, the
functional recovery correlatedwell with increased vessel formation
and enhanced BBB integrity as well as suppression of inﬂammation.
VEGF was identiﬁed as the main NPC-secreted factor responsible
for some of the effects in vivo, and pre-treatment of grafted human
NPCs with the humanized anti-VEGF-A monoclonal antibody Bev-
acizumab signiﬁcantly reduced the NPC-mediated neo-
vascularization in the peri-infarct cortex [105]. Moreover, NPC-
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macrophages in the peri-infarct cortex, compared with sham-
treated controls. Again, this anti-inﬂammatory effect was
completely neutralized by Bevacizumab treatment, thus implying
that NPC-secreted VEGF was important for both pro-angiogenic
and immune regulatory effects [105].
Transplanted NPCs also show remarkable immune regulatory
properties in vitro and also in vivo after transplantation into animal
models of MS, SCI and stroke [3,7,106]. However, only a few reports
have shown neat evidence of the effects of grafted NPCs on the host
immune system. Injecting NPCs subcutaneously (s.c.) into mice with
relapsing EAE, rather than intravenously, has turned out to be a smart
approach to have transplantedNPCs predominantly target secondary
lymphoid organs e where their interactions with the host immune
cells can be studiedewith a negligible accumulation into the CNS. In
fact, s.c.-injected NPCs accumulate and survive over 2months within
draining lymph nodes, where a focal up-regulation of major devel-
opmental stem cell regulators, such as bone morphogenetic protein
(BMP)-4, Noggin and Sonic hedgehog are observed [3]. Ex vivo studies
showed a signiﬁcant down-regulation of the co-stimulatory mole-
cules CD80/B7.1 and CD86/B7.2 on DCs extracted from the lymph
nodes of NPC-injected EAEmice, and this ﬁndingwas also conﬁrmed
within in vitro NPC/DC co-cultures. Further in vitro experiments
identiﬁed a novel, highly NPC-speciﬁc, BMP-4-dependent mecha-
nism hindering DC maturation that was advocated as crucial. The
evidence that BMP-4 plays a central role in DC maturation was pro-
vided by using BMP antagonist Noggin, which reverted the antigen
presentation capacity of naive PLP-pulsed DCs co-culturedwith NPCs
invitro. Thiswas theﬁrst identiﬁcationof amemberof theTGF-b/BMP
family of stem cell developmental regulators as a novel tolerogenic
factor released by immune regulatory NPCs. A more recent study has
shown that the intravenous administration of NPCs ameliorates EAE
by selectively inhibiting the differentiation of encephalitogenic T
helper 17 (Th17) cells through secreted factors. Cao et al. also iden-
tiﬁed LIF as the key factor responsible for the observed inhibition of
Th17 cell differentiation mediating the efﬁcacy of NPCs in EAE, and
elucidated the signalling pathway behind this novel mechanism of
action, where LIF antagonizes interleukin (IL)-6-induced Th17 cell
differentiation through Extracellular signal-regulated kinase (ERK)
and Suppressor of cytokine signalling (SOCS)3-dependent inhibition
of Signal transducer and activator of transcription (STAT)3 phos-
phorylation [107].
High levels of nitric oxide (NO) and PGE2 were detected in the
supernatants of NPCs co-cultured with T cells. Both NO and PGE2
were induced in T cells co-cultured with NPCs, compared with T
cells only or NPC-only control cultures, thus suggesting that in-
teractions with T cells might promote or enhance NO and PGE2
production from NPCs [108]. Moreover, inducible NOS (iNOS) and
microsomal type 1 PGE synthase (mPGES-1) was detected only in
NPCs co-cultured with T cells, reinforcing the view that NO and
PGE2 production in NPCs is induced by activated T cells. To deter-
mine whether NO and PGE2 were involved in T cell suppression by
NPCs, speciﬁc inhibitors for NO and PGE2 production were inves-
tigated and found to restore T cell proliferation [108].
NPC-secreted heme oxygenase-1 (HO-1) has also been impli-
cated in T cell suppression, as shown by partial loss of immune
suppressive (e.g. anti-proliferative) effects in NPCs pre-treated with
the competitive inhibitor of HO-1 protoporphyrin IX (SnPP) prior to
being co-cultured with T cells [109].
All these studies conﬁrm the importance of the interactions
between NPCs and immune cells to reconﬁgure the deleterious
inﬂammatory environment and thus promote the healing or
regeneration processes. While the description of the processes
involved in NPC protection is still a matter of intense investigation,
the ability of NPCs to secrete neuroprotective and immunemodulatory factors is remarkable, and indicates that there is a lot
more to learn about functional stem cell plasticity.3. Extracellular membrane vesicles as specialized cargoes of
the stem cell secretome
In addition to paracrine soluble factors that stem cells release at
the level of the extracellular space, intensive research efforts are
being devoted to investigating the role of secreted EVs in the
therapeutic potential of stem cells [110,111]. EVs can be considered
as paracrine or endocrine signalling vehicles, given that they might
transport deﬁned signalling molecules such as cytokines to target
cells at distant sites [112e114]. To date, the biochemical composi-
tion, the complex biogenesis of these vesicles, and their physio-
logical role have only partially been elucidated. Despite the lack of
detailed characterization, their potential as mediators of cell
communication has not gone unnoticed, since these vesicles have
remarkable features, including the ability to transfer proteins and
functional genetic materials such as micro RNAs (miRNAs) to other
cells [115e119]. It is also worth noting the bidirectional exchange of
information between stem cells and target cells with EVs released
from stem cells that may confer a stem-cell-like phenotype to
injured cells, leading to the activation of self-regenerative programs
[110]. On the other hand, EV-mediated transfer of tissue-speciﬁc
information from injured (host) cells to grafted stem cells may
reprogram the latter to gain phenotypic and functional character-
istics of the cell of origin. It would seem likely that the potential of
meaningful repair of the brain after injury will depend on the bi-
directionality of this communication [9]. To date, only a few
studies have been conducted that have characterized the protein
composition of MSC-derived EVs in more detail [120], with the
genetic cargo of EVs being the most thoroughly analysed compo-
nent [116].
Liquid chromatography (LC)/MSeMS analysis of the MSC-EVs
proteome identiﬁed 730 proteins, with features common with
EVs derived from other types of cells as well as some distinct to
MSC-EVs. The MSC-EVs proteome integration with MSC self-
renewal and differentiation-related genes, and the proteome of
MSC-conditioned media, provides a list of candidate molecules and
their associated pathways through which MSC-EVs can promote
the therapeutic effects including surface receptors like platelet-
derived growth factor receptor (PDGFRB); signalling molecules
like mitogen-activated protein kinase 1 (MAPK1); cell adhesion
mediators like ﬁbronectin 1 (FN1); and MSC-associated antigens.
The MSC-EV proteome was also proﬁled by MS and antibody array
by Lai et al., who succeeded in identifying 857 proteins [119]. A
predominant feature of the MSC-EV proteome was the presence of
all a and b chains of the 20S proteasome and the three beta sub-
units of the immunoproteasome, which correlated with a signiﬁ-
cant reduction of the oligomerized protein in vivo in mice with
myocardial infarction treated with MSC-EVs [119,121].
Katsuda et al. proposed the use of adipose tissue-derived MSC-
EVs as a promising approach to delivering the most important b
amyloid (Ab)-degrading enzyme neprilysin (NEP) peripherally and/
or directly into the brain in AD [122]. Immunoblot analyses
revealed that exosomes (a class of EVs) secreted by ASC-MSCs
contain NEP and the enzyme activity assay conﬁrmed that these
exosomes exhibit NEP-speciﬁc activity only in ASC-MSC-derived
exosomes, but not in BM-MSC exosomes. ASC-MSC-derived exo-
somes were transferred into N2a cells overproducing Ab as shown
by co-cultures of PKH26-labelled ASC-MSCs with PKH67-labelled
N2a cells, and were suggested to decrease both secreted and
intracellular Ab levels. This was the ﬁrst report of the isolation of
exosomes containing enzymatically active NEP from cultured cells,
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EVs derived from MSCs expressed regulatory molecules such as
programmed death ligand-1 (PD-L1), galectin-1 and membrane-
bound TGF-b as detected by ﬂow cytometry [123]. Based on these
ﬁndings, ex vivo immunemodulatory effects of MSC-derived EVs on
antigen-activated EAEmice lymphocytes were investigated. Results
showed that EVs effectively inhibit auto-reactive lymphocyte acti-
vation and proliferation, and promote the secretion of lymphocyte-
derived anti-inﬂammatory cytokines like IL-10 and TGF-b. This
provides evidence that MSC-derived EVs serve as vehicles for
several MSC-speciﬁc tolerogenic molecules. Besides the involve-
ment of MSC-EVs in the induction of immune tolerance, the evi-
dence that the immune modulatory effects of NPCs might also be
partially mediated by EVs arises from in vitro experiments in which
the culture supernatants of NPCs suppress the activation and pro-
liferation of T cells by apoptosis and the cell cycle arrest. Isolated
EVs added to the supernatant of cultured T cells result in a similar
suppression by G0/G1 cell cycle arrest [124].
In addition to the release of soluble factors, the beneﬁcial effects
observed following stem cell therapies in regenerative medicine
could rely on the secretion of pro-regenerative signals delivered by
EVs. Systemically MSC-secreted EVs were found to have the same
beneﬁcial effect in protecting against ischaemiaereperfusion-
induced acute and chronic kidney injury by inhibiting apoptosis-
stimulating tubular epithelial cell proliferation and signiﬁcantly
reducing the impairment of renal function [125]. In this experi-
mental model, the effect of EV injection was comparable to that
observed withMSCs, indicating that EVs mimic a substantial part of
the beneﬁcial effects of the cells of origin. This in turn suggests that
EVs mediate, at least partly, the MSC-regenerative potential,
opening up new potential applications of EVs as specialized secre-
tome cargoes.
While the beneﬁcial and protective effects of EVs secreted by
MSCs in tissue repair have been reported in heart [121] and kidney
pathological conditions, their use for brain repair is still not well
characterized in in vivo models. Nevertheless, as a bi-lipid mem-
brane vesicle with many membrane-bound proteins and a diverse
cargo, EVs may represent an ideal therapeutic agent that has the
potential to home to target tissues and treat neurological diseases.
With that aim in mind, a more in-depth characterization of the
neurotrophic and regenerative factors present in the EV cargoes
secreted by both MSCs and NPCs is mandatory in the attempt to
select and identify the molecules responsible for the therapeutic
effects of the SCS.
4. Investigative directions in characterizing the stem cell
secretome
The new emerging view e that is, to foster the repair of an
injured tissue by harnessing the paracrine factors instead of using
whole cells e introduces a radically different dimension to the
therapeutic applications of MSCs and NPCs in regenerative medi-
cine. This has alerted the scientiﬁc community to the challenging
investigation of the secreted molecules in the SCS, be they soluble
or delivered by EVs, which may be responsible for some of the
beneﬁcial effects observed after stem cell transplantation.
These efforts have been greatly facilitated by signiﬁcant tech-
nological advances in the ﬁeld of proteomics during the last two
decades [126]. Despite this potential, the knowledge of the secreted
proteins in mediating MSCs and NPCs function is still very limited.
The most commonly used approaches to identifying secreted pro-
teins include gel-based (2-D or 2-D Fluorescence Difference Gel
Electrophoresis (DIGE)) or gel-independent (1-D or 2-D LCeMS/
MS) techniques [127]. The highly bioactive molecules secreted inthe SCS are often difﬁcult to identify using conventional gel-based
techniques; LCeMS/MS is currently the preferred approach, often
employed in conjunction with isobaric quantiﬁcation with stable
isotope labelling with amino acids in cell culture (SILAC), isobaric
tag for relative and absolute quantitation (iTRAQ) or isotope-coded
afﬁnity tag (ICAT) labelling. With this aim, multiplex antibody-
based techniques offer high sensitivity (typically 1e10 pg/ml) as
well as high speciﬁcity, reproducibility across a broad range of
concentrations, and the potential for massively parallel experi-
ments. This multiplexing methodology can be used on planar
microspot array (e.g. RayBio cytokine arrays) or bead-based assays
(e.g. Luminex xMAP technology). The limitation of the targeted
antibody-based methods lies in the pre-selection of the analytes
included in the assay and the exclusion in the assay panel of those
molecules with speciﬁc antibodies not commercially available. On
the other hand, an untargeted proteomic approach will allow a
huge range of molecules to be covered, the most intriguing aspect
being to discover new, undeﬁned secreted factors that are thera-
peutically relevant to the SCS.
Mouse and human MSC SCS have been recently characterized
using mostly LCeMS/MS approaches [128e134]. Sze et al. have
provided the whole spectrum of secretory proteome of human
embryonic stem (ES) cell-derived MSCs, which was consistent with
the reported paracrine effects of whole (parental) MSCs on different
cellular systems and diseases [135]. By using a combination of two
techniques e LCeMS/MS and antibody arrays e they suggested a
molecular basis for the use of MSC-CM in modulating repair after
injuries. Although shotgun proteomics analysis by LCeMS/MS is a
sensitive technique and has high throughput capability, it is difﬁ-
cult to detect small proteins/peptides, which include most of the
cytokines, chemokines, and growth factors. This was partially
overcome by the use of antibody arrays (RayBio cytokine arrays)
increasing the reproducibility of the proteomic proﬁling of the MSC
secretion in vitro. The resulting proteomic proﬁle of secretion by
MSCs included almost all the cytokines and chemokines that were
previously reported [132] to be secreted by MSCs, such as
epithelial-derived neutrophil-activating peptide 78 (ENA78),
growth factors (VEGF, HGF), growth factor-binding proteins such as
insulin-like growth factor binding protein 2 (IGFBP2), cytokines (IL-
1 b, IL-6, IL-8, TGF-b) and tissuemetalloproteinase inhibitors (TIMP)
1 and 2. From the total number of 201 unique proteins (132 using
LCeMS/MS and 72 using antibody array) identiﬁed in the cultured
medium, more than 85% were validated at the mRNA level by cDNA
microarrays or quantitative RT-PCR. In addition, computational
analyses were used to predict the roles of the SCS components in
metabolism, angiogenesis, immune response and differentiation,
providing molecular support for an MSC-mediated paracrine effect
on tissue repair and regeneration in MSC transplantation studies
[132].
To characterize the MSC SCS, Sarojini et al. applied the LCeMS/
MS proteomic approach to MSC-CM and identiﬁed 19 secreted
proteins including extracellular matrix structural proteins, collagen
processing enzymes, pigment epithelium-derived factor (PEDF)
and cystatin C (Cys C). MSC SCS has been shown to induce the
chemotactic response of human ﬁbroblasts, with PEDF being the
most abundant protein in the SCS and the predominant ﬁbroblast
chemoattractant in the conditioned medium evaluated by immu-
nodepletion and reconstitution experiments [133]. Later, the same
authors, by using LCeMS/MS, identiﬁed cysteine-rich protein 61
(Cyr61) in the MSC SCS that contributes to the promotion of
angiogenesis, as previously reported [129]. By using angiogenesis
assays, they demonstrated that the MSC’s SCS promotes the
morphogenesis of endothelial cells in a dose-dependent manner
in vitro, as well as neovascularization in vivo. In addition, the
immunodepletion of Cyr61 abrogates the pro-angiogenic effect of
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recombinant Cyr61 to the depleted SCS restores its pro-angiogenic
effects, thus conﬁrming that Cyr61 is one of the key factors in the
MSC SCS promotion of vasculature remodelling. Collectively, these
data suggest that MSCs secrete a panel of functionally active factors
that act in the healing of the injured tissue microenvironment.
MSC-secreted chemoattractants, such as PEDF, eventually stimulate
the migration of ﬁbroblasts that is important for scaffold building,
while the secretion of Cyr61 promotes neovascularization [129].
Mouse bone marrow stromal cell-derived NPCs provide a pro-
tective function by secreting prosaposin (PSAP), a protein that is
capable of rescuing mature neurons from apoptotic death. This
factor is identiﬁed as the lead protein in the SCS of NPCs by tandem
mass spectroscopic proﬁling, and further validated by western
blotting and immunocytochemistry [131]. In this study, the NPC SCS
protected from apoptotic death induced by 6-OHDA in cultures of
rat PC12 neuronal cells, human ReNcell CX cell-developed neuronal
cultures and rat cortical primary neurons. The proof that PSAP is a
key factor in this protection was achieved by using SCS immuno-
depleted of PSAP that lacked the anti-apoptotic effect of SCS, as well
as by adding the recombinant peptide of PSAP in the NPC SCS that
prevented cell death [131]. Aside from PSAP, six other secreted
proteins were detected in the NPC SCS by LCeMS/MS analysis, such
as collagen a-2(I) chain (COL1A2), ﬁbronectin (FN), granulin (GRN),
Cys C, neurotensin (NT)/neuromedin N (NN) and secreted protein
acidic and rich in cysteine that can be further investigated for the
anti-apoptotic activity in mature neurons [131].
Dahl et al. were the ﬁrst to combine two-dimensional gel elec-
trophoresis (2-DE) and mass spectrometry to characterize the
secreted factors in conditioned media of rat neural hippocampal
progenitor cells [136], conﬁrming the practicality of proteomic
analysis to decipher the molecular aspect of SCS. The authors suc-
ceeded in the identiﬁcation of a number of stem cell factors in NPC-
CM, which included Rho-guanine nucleotide dissociation inhibitor
1 (RhoGDI), phosphatidylethanolamine binding protein (PEBP),
polyubiquitin, immunophilin FK506 binding protein 12 (FKBP12)
and Cys C [136].
Several other studies identiﬁed major NPC intracellular pro-
teins signiﬁcantly regulated during neural stem cell differentia-
tion using mostly 2-DE and LCeMS/MS approaches [137], most of
them are actually focused on the proteome of cell lysates rather
than the characterization of the SCS itself except for proteomic
comparative studies of proteins secreted from neurons, astrocytes
and the rat adult hippocampal nerveeglial precursor cell line
[138]. In addition to adhesion and antioxidant proteins, including
glutathione S-transferases and peroxiredoxins, this study showed
that the composition of the NPC-secreted proteins contains some
molecules, such as protein molecular chaperones, proteasome
subunits, and metabolic enzymes that lead to the identiﬁcation of
new roles for the extracellular space within the CNS. The most
unexpected groups of proteins found outside the cell are those
involved in carbohydrate metabolism, such as lactate dehydro-
genase, creatine kinase, and malate dehydrogenase [138]. More-
over, this comparative study showed that the repertoire of
secreted proteins is unique for each cell type and represents a
distinct set of molecular identiﬁers for individual phenotypes
within the CNS.
Roche et al. provided a comparative proﬁling of the SCS of hu-
man ES cells, MSCs and marrow isolated adult multilineage
inducible (MIAMI) cells to address the molecular and cellular basis
of their regenerative potential [126]. This proteomic screening es-
tablishes the closer relationship between MSCs and MIAMI cells,
while ES cells were more divergent. Proteins characteristic of MSCs
include transgelin-2 (TAGLN2), phosphatidylethanolamine-binding
protein 1 (PEBP1), heat-shock 20 kDa protein (HSP20/HSPb6), andprogrammed cell death 6-interacting protein (PDC6I), among
others. These comparative studies are very useful in providing a
general SCS overview, since the poly-pharmacies secreted by MSCs
or NPCs are potentially more important than any single factor in
stimulating CNS repair.
Nonetheless, the key (still unsolved) challenges in SCS analysis
include the interference of serum proteins in the pure cell popu-
lation from the donor tissue that contain many overlapping com-
ponents and can interfere with the detection.
To overcome this problem, cells are often cultured in serum-free
media or media with deﬁned components including eventually the
analysis of unconditioned medium to identify possible serum
contaminants. Remarkably, a number of multiplex methods
(RayBio cytokine arrays or Luminex xMAP technology) have
been developed, allowing the detection and quantiﬁcation of up to
several hundred analytes in a single sample simultaneously, even in
the presence of serum, thanks to the calibration standards diluted
in unconditioned medium [139]. Another solution to avoid the
background of serum-containing media has been developed
exploiting the combination of click chemistry and pulsed SILAC to
selectively enrich and quantify secreted proteins [140]. This study
emphasises the need for careful evaluation of SCS proﬁling, since
serum starvation has a strong impact on the secretion of many
biologically important proteins, such as cytokines and growth fac-
tors. In addition, the combination of in-depth proteome proﬁling
and the ability to resolve protein secretion over very short time
spans will be especially helpful in investigating the regenerative
properties of the SCS.
Therefore, better characterization of the SCS, challenging the
discovery of new potential regenerative factors, will be achieved by
the application of unbiased global discovery techniques, such as LC/
MS and the correlation of the resulting data with those obtained by
complementary approaches, such as ELISA- or Luminex-based
assays [141]
Moreover, based on the detection of metabolic enzymes in the
extracellular space within the CNS and secreted by the rat adult
hippocampal nerveeglial precursor cell line [138], the metab-
olomics of the SCSwould be promising in improving the knowledge
of the metabolic processes accompanying and underpinning stem
cell-secreted signalling. In contrast to classical biochemical ap-
proaches that often focus on single metabolites, metabolomics is
emerging as a powerful tool in CNS research involving the collec-
tion of quantitative data on a broad series of metabolites in an
attempt to gain an overall understanding of metabolism and/or
metabolic dynamics associatedwith conditions of interest [142]. All
these techniques are complementary, and the combination of
protein abundance data generated via a proteomic approach and
the metabolic data from a metabolomic study should both facilitate
the global comprehension of changes in SCS proﬁles under different
conditions in regenerative medicine.
The ﬁrst attempt at applying metabolomic proﬁling to SCS
characterization has been carried out by Cezar and co-workers,
who measured and identiﬁed small molecules secreted by human
ES cells and ES cell-derived NPCs in response to valproate for
developmental toxicity testing [143]. To date, metabolomic reports
on the SCS in CNS regenerative medicine are still not available,
except for a MSC SCS metabolomic characterization in the context
of biomaterials designed for orthopaedic application [144]. Three
case studies were reported to illustrate the application of metab-
olomics to the study of MSC responses to titania-nanopillared
substrata. The results highlighted that L-ornithine was a key
metabolite signiﬁcantly modulated in abundance among different
heights of substrata. Therefore, increased understanding of the
metabolites that become depleted or that accumulate in the me-
dium during the acquisition of a speciﬁc stem cell fate might
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differentiation, the SCS being regulated in the microenvironment
and, and of predicting the likely changes that the host would make
in response to stem cell- or stem cell free-based regenerative
strategies.
5. Investigative directions to improve the stem cell secretory
activities
The current approaches to increasing the production of desired
trophic and immune regulatory factors, thus augmenting stem cell
paracrine effects, involves (i) different preconditioning strategies
that include hypoxic exposure, exposure to cytokine cocktails [14]
and preconditioning through cellecell interactions, or alterna-
tively (ii) gene expression approaches to stem cell engineering.
5.1. Stem cell preconditioning
MSCs placed under serum-deprived conditions mimicking an
in vitro model of ischaemia and hypoxic preconditioning, secreted
increased levels of pro-survival and pro-angiogenic autocrine,
paracrine, or juxtacrine factors that include VEGF-A, angiopoietins
(ANGPTs), IGF-1, and HGF [145]. The mechanism of this hypoxia-
induced preconditioning correlated with the induction of the
hypoxia-inducible factor (HIF), a transcription factor that binds to
the hypoxia response elements in a number of HIF target genes,
leading to hypoxia-induced protection against brain ischaemia
[146].
Rats with experimental traumatic brain injury (TBI) infused
through the tail vein with human MSC-CM collected from hypoxic
in vitro preconditioning performed signiﬁcantly better in both
motor and cognitive function tests and showed increased neuro-
genesis and decreased brain damage, compared with TBI rats
treated with MSC-CM collected from normoxic in vitro pre-
conditioning [147]. In vitro hypoxic preconditioning was found to
enhance the secretion of bioactive factors by MSCs, including HGF
and VEGF [147]. Moreover, pro-inﬂammatory cytokines such as
IFN-g, TNF-a and IL-1a or IL-1b were required to induce immuno-
suppression by MSCs through the concerted action of chemokines
and NO [148]. To determine whether cytokines secreted by acti-
vated T cells induce immunosuppression by MSCs the authors used
neutralizing antibodies against various cytokines in the anti-CD3-
activated splenocyte supernatant (SupCD3-act), before its addi-
tion to co-cultures with MSCs. The treatment with anti-IFN-g an-
tibodies completely restored the proliferation of T cell blasts co-
cultured with MSCs supplemented with SupCD3-act, thus con-
ﬁrming the indispensable function of soluble IFN-g in T cell pro-
liferation. Moreover, the simultaneous neutralization of TNF-a and
IL-1a and IL-1b in SupCD3-act before its addition to the MSC-T cell
co-cultures completely reversed the inhibition of T cell prolifera-
tion, while the antibodies had no effect, neither individually nor in
pairs. Therefore, IFN-g synergized with TNF-a and IL-1a or IL-1b to
promote the anti-proliferative effects of MSCs on T cells [148].
Furthermore, MSCs from mice deﬁcient in IFN-g receptor 1 (IFN-
gR1/) were incapable of suppressing anti-CD3-induced spleno-
cyte proliferation in co-cultures [148].
MSCs responded to IFN-g in a dose-dependent manner in vivo,
with increased concentrations of IFN-g being more efﬁcient at
eliciting higher MSC-mediated immune regulatory effects [149].
Several in vitro and in vivo data are available supporting the role of
MSC licensing in the induction of measurable and effective immune
regulation [150].
Since pro-inﬂammatory cytokines have been shown to be
essential for the activation of some stem cell-dependent functional
effects, it can be reasoned that preconditioning stem cells withcytokines in vitro (e.g. prior to cell transplantation) would augment
their modulation of the host immune response through paracrine
factors. In the attempt to exploit the synergic effects, a cocktail of
cytokines, conditioned medium or serum has been employed to
stimulate MSCs in vitro. Incubation of MSCs with inﬂammatory-like
serum harvested from LPS-stimulated rats induced reactive secre-
tion of a soluble form of TNF receptor 1 (sTNFR1) in vitro [151]. The
reactivity of this secretion was conﬁrmed by the activation of the
TNFR1 downstream nuclear factor kappa-light-chain-enhancer of
activated B cells (NFkB) complex signalling pathway in target cell
lines that express green ﬂuorescent protein (GFP) under the control
of the NFkB promoter. The contribution of NFkB complex to the
reactive secretion of sTNFR1 from MSCs was demonstrated in
alteration of the protein secretion. Moreover, the blockage of the
reactive secretion of sTNFR1when using a speciﬁc inhibitor peptide
of NFkB suggested once again that the anti-inﬂammatory ability of
MSC is not innate, but is rather induced by the surrounding in-
ﬂammatory cytokines. The reactive secretion of sTNFR1 by MSCs
was also observed after treatment with neutralizing anti-sTNFR1
antibodies, suggesting that NFkB activation in MSCs is regulated
by multiple, not necessarily redundant, functional cytokine re-
ceptors [151].
In vitro preconditioning with IL-6 enhances the therapeutic ef-
fects of the transplantation of NPCs in experimental ischaemic
stroke in mice [152]. Syngeneic NPCs harvested from the foetal SVZ
were preconditioned with IL-6 in vitro and then intracerebrally
transplanted 6 h or 7 days after transient MCAo. IL-6 pre-
conditioning protected the grafted neural stem cells from ischae-
mic reperfusion injury through up regulation of manganese SOD2, a
primary mitochondrial antioxidant enzyme, and induced secretion
of VEGF with the resulting promotion of angiogenesis. Further-
more, transplantation of IL-6-preconditioned NPCs signiﬁcantly
attenuated infarct size and improved neurological performance,
compared with MCAo mice transplanted with non-preconditioned
NPCs. By taking advantage of RNA interference against STAT3 on
NPCs before transplantation, the authors also demonstrated that
this IL-6-induced amelioration of ischaemic insults was due to the
activation of STAT3 [152].
A better understanding of how the cytokines expressed in the
CNS inﬂammatory or ischaemic environment in vivo modulate the
therapeutic effects of MSCs or NPCs is therefore a prerequisite to
developing more effective protein-based pre-conditioning
approaches.
Promotion of cell-to-cell interactions within the heterogeneous
stem cell population itself has a profound impact on the SCS [153].
In vitro 3D culture methodologies facilitate greater cell-to-cell
contact and interactions of cells with the extracellular matrix
(ECM), allowing cells to adapt to their native morphology, which
may affect this signalling activity [154]. As such, aggregation of
human MSCs in culture with 3D spheroids provides an effective
procedure in prompting the MSCS to secrete tumour necrosis
factor-inducible gene 6 protein (TSG-6), and thereby, enhance
their anti-inﬂammatory effects [153]. The spheroid-human MSCs
hybrid aggregates also secrete high levels of stanniocalcin-1
(STC-1), a protein with both anti-inﬂammatory and anti-
apoptotic properties. The increased secretion of TSG-6 and STC-1
is also consistent with the enhanced suppression of inﬂamma-
tory responses in spheroid-human MSCs hybrid/LPS-activated
macrophage co-cultures [153].
This mechanical pre-conditioning could offer less control for the
SCS components than other physiological and molecular ap-
proaches like hypoxia or cytokine preconditioning. On the other
hand, the impact of these later pre-treatments is transient owing to
the self-regulatory mechanisms. In this line, stem cell engineering
has the advantage of achieving sustained responses.
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Stem cells have been genetically engineered with a number of
transgenes tomore effectively secrete increased amounts of (tissue)
trophic factors. Several approaches to genetically modifying stem
cells, including viral and non-viral delivery of technologies, have
been used to force/increase the secretion of soluble proteins and to
control the SCS in vivo, after transplantation [14].
After the transplantation of genetically engineered MSCs as the
delivery vehicles of BDNF, NGF or VEGF, signiﬁcant behavioural
recovery and reduction of striatal degeneration was observed in
mice with experimental HD [155e157].
The intracerebral transplantation of MSCs modiﬁed to over-
express BDNF was also signiﬁcantly more efﬁcacious in eliciting
functional recovery in rats with experimental brain ischaemia,
many of the improvements correlating well with the presence of
fewer apoptotic cells in the ischaemic boundary zone in vivo [158].
Early (24 h) intracerebral transplantation of MSCs modiﬁed to
overexpress VEGF also improved neurological deﬁcits and reduced
infarction volume in MCAo rats [159].
The intrastriatal injection of human umbilical cord mesen-
chymal stem cells (HUMSC) modiﬁed to overexpress VEGF led to a
signiﬁcant reduction of apomorphine-induced rotations, and a
revival of tyrosine hydroxylase (TH) immunoreactivity at the level
of the lesioned striatum and substantia nigra in rotenone-induced
experimental chronic PD rats [160]. A key ﬁnding of this study
was that VEGF overexpression not only protected host DA neurons,
but also increased the levels of endogenous VEGF in the striatum,
and promoted the direct differentiation of grafted HUMSCs intoTH-
positive neurons in vivo [160].
Overexpression of GDNF in human NPCs provided protection
from nitroprusside-induced apoptosis in vitro; while the trans-
plantation of xenogeneic NPC-GDNF directly into the brain of TBI
rats showed much higher survival, migratory capacities towards
the lesion and neurogenic potential, and led to better cognitive
functions as early as 6 weeks after transplantation, compared with
TBI rats transplanted with untransduced control NPCs [161].
NPC-VEGF showed increased survival, and provided higher
neuroprotection, neoangiogenesis, protection from apoptotic cell
death and functional recovery after transplantation into the cere-
bral cortex of mice with experimental intracerebral haemorrhage
(ICH), compared to control NPCs [162].
Galectin (Gal)-1 is expressed in the adult brain by NPCs of the
SVZ [163] and hippocampus [164]. This soluble lectin is also
expressed around infarcted tissue after brain ischaemia and was
found to inhibit the proliferation of astrocytes in a dose-dependent
manner, attenuate astrogliosis and down-regulate the astrogliosis-
associated expression of iNOS and IL-1b after brain ischaemia [165].
Following these observations, human NPC-Gal-1 were gener-
ated and transplanted into rodents with experimental unilateral
focal brain ischaemia, thus reducing the total ischaemic volume and
improving the recovery of motor deﬁcits, compared with untrans-
duced control NPCs [165e168].
NPCs overexpressing IL-10, an anti-inﬂammatory cytokine that
efﬁciently suppresses EAE [169], showed an enhanced ability to
promote remyelination, neuronal repair and immune suppression
(both in the spinal cord and in the CNS), compared with untrans-
duced NPCs, when systemically injected into EAE mice [170].
Many CNS diseases are due to the lack of a crucial enzyme, such
as b-galactocerebrosidase (GALC) in the pediatric leukodystrophies
[171]. Mouse NPCs, either untransduced or genetically modiﬁed to
express supranormal levels of GALC, were transplanted directly into
the brain of twitcher mice. NSC rapidly engrafted, migrated and
stably expressed GALC in vivo, which widely distributed through
the cerebrospinal ﬂuid (CSF) and reached the whole brain and thespinal cord. Supraphysiological levels of GALC in donor cells
resulted in enhanced metabolic reconstitution of host CNS tissue,
which was mediated by cross-correction, the mechanism by which
secreted lysosomal enzymes are uptaken by neighbouring cells. The
levels of enzymatic reconstitution/correction correlated well with
the reduction of tissue storage, decrease of activated astroglia and
microglia, modulation of inﬂammation, and improved survival
[171].
Thus, besides the secretion of cytokines and growth factors, the
therapeutic effects of NPCs have been ascribed to the release of
therapeutic enzymes that are taken up by cross-correction mech-
anisms to enzyme-deﬁcient host brain cells. In this perspective, the
genetic manipulation of NPCs applied to metabolic correction via
secreted enzymes is another way to exploit the SCS potential and
becomes crucial to counteract/prevent irreversible CNS damage.
As the biology mediating the therapeutic beneﬁt of the MSC and
NPC secretome becomes more deﬁned, targeted SCS pre-
conditioning and genetic manipulation approaches will likely be
useful in enhancing therapeutic relevance.
6. Conclusions and future perspectives
Based on the encouraging pre-clinical results [172,173], a new
paradigm has been proposed concerning the ability of implanted
MSCs and NPCs to foster restorative endogenous responses via
bioactive molecules secreted at the level of the injured tissue
microenvironment.
The delivery into the CNS of single cytokines identiﬁed to be
active in the SCS (e.g. the neuropoietic cytokine LIF), should in
principle stimulate the proliferation of CNS-resident progenitor
cells and increase its reparative potential; this is a strong premise
for the treatment of disorders such asMS and SCIs inwhich acute vs
chronic tissue damage leads to accumulating and irreversible
disability [174].
However, the outcomes from early clinical trials with single
cytokines for brain or cardiovascular diseases have failed to meet
expectations [175,176]. The brain injection of HGF [177,178] has
been tested in vivo and can be seen as the ﬁrst attempt with a single
molecule to harness the therapeutic potential of the SCS.
The intracerebroventricular [179] or putaminal [180,181] infu-
sion of GDNF has recently shown to be an effective treatment for
PD, with clinical trials currently in progress [182]. Trials with NGF
for AD are ongoing, with the growth factor either given as infused
protein [183], released in situ by implanted NGF-secreting cells
[184] or adeno-associated gene delivery [185]. Preclinical data with
BDNF also show much promise, yet there are accompanying difﬁ-
culties mainly due to the short serum half-life, low distribution rate
and poor access to the CNS by the systemically-injected protein
[182].
The safety, tolerability and efﬁcacy of single cytokine/growth
factor therapies are matter of great debate in these clinical trials and
the clariﬁcation of these issues will set the stage to think on the
biosafety of the SCS, as plausible alternative. In fact, stem cells do not
just secrete growth factors and/or cytokines, but instead release a
wide range of products that can encourage the growth and even
supplement (host) cells [141,186]. Multiple cytokines/growth factors
may need to be administered simultaneously at different concen-
trations and time points to act synergistically to achieve a thera-
peutic effect. As such, the application of SCS in regenerativemedicine
is now opening new frontiers in the treatment of a potentially long
list of neurological disorders [187], the characterization of the SCS
being one of the main challenges of next-generation ‘-omics’ applied
to stem cells and regenerative neuroscience.
Some practical considerations for harnessing the SCS in exper-
imental and clinical settings need to be posed.
D. Drago et al. / Biochimie 95 (2013) 2271e22852280First, the limitations of cytokine-based therapy aremostly due to
tissue transport, pharmacokinetics and protein stability, and this
reinforces the need to develop controlled release and delivery
strategies for the SCS. While the use of preconditioned media
eliminates the need for direct injection of cells, the coupling of
preconditioned media with bioengineered materials may increase
the effect of these cytokines and chemokines and possibly extend
the duration of their therapeutic effects. Substantial progress in the
development of novel nanoﬁbres for the delivery and controlled
release of bioactive molecules has been made in recent years [188].
Wang and co-workers provided the ﬁrst example of the effect of
preconditioned nanoﬁbres with ES cells for the recovery from
lipopolysaccharide (LPS)-induced acute kidney injury in vivo [189].
Similarly encouraging results have been obtained with nanoﬁbre
hydrogels that act as sponges, thus soaking up the SCS while being
separated from the stem cells themselves via a permeable mem-
brane [190]. During incubation, the peptide gel is not in contact
with the cells, but still permeable enough for the SCS to diffuse
through the culture medium and into the gel. After this pre-
conditioning step, the hydrogel can be used in a cell-free manner to
treat the condition of interest [190].
A second relevant issue is the identiﬁcation and characterization
of stem cell EV cargoes and their exploitation as a secretome
therapeutic component and natural delivery system that remain
elusive. Alvarez-Erviti succeeded in delivering functional siRNA to
the mouse brain by systemically injecting targeted exosomes [191].
This was the ﬁrst demonstration of a naturally occurring exosome-
based drug delivery system focused on speciﬁc secretome compo-
nents. Based on the fact that EVs have similar beneﬁcial effects in
regenerative therapy to donor cells [112,125,192], producing EVs
from stem cells could be envisaged, holding promising therapeutic
relevance in brain repair on a large scale and even modifying their
composition. This could be achieved by in vitro manipulation of
stem cells to enhance secretion of pro-regenerative factors and the
development of novel therapeutic strategies by using in vitroFig. 1. Proposed model for the therapeutic application of mesenchymal/neural stem cell sec
lead to remarkable tissue trophic effects on endogenous brain cells and beneﬁcial modulat
healing of the injured CNS. The characterization of the SCS is one of the main challenges of pr
with bioengineered materials may be employed to control and sustain the expression of custgenerated and modiﬁed MVs enriched with growth factors, cyto-
kines, chemokines and regulatory miRNAs that promote regener-
ation of damaged tissue [114].
A third important aspect to consider is the patient’s safety and
the potential beneﬁt-to-risk ratio of stem cell therapies. A number
of MSC- or NPC-based phase I and II clinical trials are being con-
ducted [193e196], and there is great expectation that these pio-
neering studies will tell more about the biosafety as well as
anticipate some efﬁcacy outcomes of non-haematopoietic stem cell
therapies for neural repair and/or restoration [193,194,197].
Furthermore, when prospecting the use of genetically engineered
stem cells, or the manipulation of secreted EVs, the risk of tumour
formation (or induction) due to insertional mutagenesis by inte-
grating technologies still raises caution for human clinical appli-
cations [198].
Fourth, at least two main aspects of interest in the ﬁeld of stem
cells are being proposed by neuroethics (topics that neurosciences
have put forth in dealingwith traditional ethics): (i) those related to
the origin of stem cells (e.g. from aborted foetuses for NPCs) and the
way in which they are obtained, studied, protected, and preserved;
and (ii) those related to the application of stem cells in neurosci-
ence, from feasibility to viability (e.g. limited in time over extensive
culturing for MSCs), risk and beneﬁt, the transplant process itself,
complications, outcome, public health impact, and also potential
deviations [199].
A ﬁfth additional main aspect to consider, which applies well
also to syngeneic stem cells exposed to an inﬂammatory envi-
ronment [9], is the immunogenicity of the graft, namely its ability
to provoke an immune response when facing the host immune
system after transplantation [200]. Some of the limitations antic-
ipated by these two latter issues should be overcome by induced
pluripotent stem (iPS) or induced stem (iS) cells, which both
provide an alternative source of functional, stably expandable
[71,201], and therapeutically efﬁcacious MSCs or NPCs for tissue
repair [202,203].retome in CNS repair. Exchange of signals between grafted MSCs or NPCs and the host
ory actions on innate and adaptive immune responses, which ultimately promote the
oteomics and metabolomics applied to neuroscience. Coupling of preconditioned media
omized secretome and possibly extend the duration of the observed therapeutic effects.
D. Drago et al. / Biochimie 95 (2013) 2271e2285 2281Although candidate molecules are under investigation, further
detailed studies are needed to carefully deﬁne the factors respon-
sible for the SCS-mediated/instructed neuroprotective and regen-
erative properties, in order to best capitalize upon this type of
therapy for the repair of neurodegenerative diseases. Elucidation of
the molecular pathways mediating stem cell SCS expression is a
crucial step towards improving our understanding of the secreted
factor proﬁle and its clinical utility [204]. Besides proteomic anal-
ysis, attempts are now being made using a next-generation
metabolomics-driven approach coupled with system biology
techniques to clarify the key metabolic pathways mediating SCS
expression. Elucidation of these mechanisms may be a crucial and
essential step in the control and improvement of SCS to maximize
therapeutic strategy in regenerative medicine.
Whereas determining the mechanism regulating the expression
of the secretome is important, the task is made more challenging
given that some of the proteins are released during cell death [127].
Therefore, the most important goal will be to move towards
methods to proﬁle the SCS in vivo that can distinguish between
factors released from the host versus those secreted by the trans-
planted stem cells that can be dynamically regulated by the local
microenvironment and harnessed in the SCS-based therapeutics.
Reaching this point will require the development of new tech-
niques that can directly quantify the dynamic expression proﬁle of
stem cells secreted factors both locally and systemically.
In conclusion, beyond the great enthusiasm for new treatment
perspectives, much investigative work is still in progress on the
development of robust and customized SCS-based future thera-
peutics, paving the way for new regenerative medicine approaches
to CNS repair (Fig. 1).
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